ページイメージ
ホームへHOME Publications

Publications

2023年

  • Wang D, Nguyen HG, Nakayama M, Oshima H, Sun L, Oshima M, Watanabe S. Mapping Nanomechanical Properties of Basal Surfaces in Metastatic Intestinal 3D Living Organoids with High-Speed Scanning Ion Conductance Microscopy. Small. 2022 Dec 11:e2206213. doi: 10.1002/smll.202206213. Online ahead of print. PMID: 36504356
  • Morita, A, Nakayama, M, Wang, D, Murakami, K, Oshima, M. Frequent loss of metastatic ability in subclones of Apc, Kras, Tgfbr2, and Trp53 mutant intestinal tumor organoids. Cancer Sci. 2023, doi: 10.1111/cas.05709. Online ahead of print.

2022

  • Liabeuf D, Oshima M, Stange DE, Sigal M. Stem Cells, Helicobacter pylori, and Mutational Landscape: Utility of Preclinical Models to Understand Carcinogenesis and to Direct Management of Gastric Cancer. Gastroenterology. 2022 Apr;162(4):1067-1087.
  • Nakayama M, Wang D, Kok SY, Oshima H, Oshima M. Genetic Alterations and Microenvironment that Drive Malignant Progression of Colorectal Cancer: Lessons from Mouse and Organoid Models. J Cancer Prev. 2022 Mar 30;27(1):1-6.
  • Yamamoto D, Oshima H, Wang D, Takeda H, Kita K, Lei X, Nakayama M, Murakami K, Ohama T, Takemura H, Toyota M, Suzuki H, Inaki N, Oshima M. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer. J Pathol. 2022 Jan 17.

2021

  • Dong Wang, Linhao Sun, Satoru Okuda, Daisuke Yamamoto, Mizuho Nakayama, Hiroko Oshima, Hideyuki Saito, Yuta Kouyama, Koshi Mimori, Toshio Ando, Shinji Watanabe, Masanobu Oshima. Nano-scale physical properties characteristic to metastatic intestinal cancer cells identified by high-speed scanning ion conductance microscope.Biomaterials. 2021 Nov 13.
  • Tsuji T, Maeda Y, Kita K, Murakami K, Saya H, Takemura H, Inaki N, Oshima M, Oshima H. FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells. Oncogene. 2021 Apr 1. doi: 10.1038/s41388-021-01757-x.
  • Kok SY, Oshima H, Takahashi K, Nakayama M, Murakami K, Ueda HR, Miyazono K, Oshima M. Malignant subclone drives metastasis of genetically and phenotypically heterogenous cell clusters through fibrotic niche generation. Nat Commun. 2021 Feb 8;12(1):863.

2020

  • Nakayama M, Hong CP, Oshima H, Sakai E, Kim SJ, Oshima M. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nat Commun. 2020 May 11;11(1):2333.

2019

  • Oshima H, Kok SY, Nakayama M, Murakami K, Voon DC, Kimura T, Oshima M. Stat3 is indispensable for damage-induced crypt regeneration but not for Wnt-driven intestinal tumorigenesis. FASEB J. 2019 Feb;33(2):1873-1886.
  • Han TS, Voon DC, Oshima H, Nakayama M, Echizen K, Sakai E, Yong ZWE, Murakami K, Yu L, Minamoto T, Ock CY, Jenkins BJ, Kim SJ, Yang HK, Oshima M. Interleukin 1 Up-regulates MicroRNA 135b to Promote Inflammation-Associated Gastric Carcinogenesis in Mice. Gastroenterology. 2019 Mar;156(4):1140-1155.e4.
  • Echizen K, Horiuchi K, Aoki Y, Yamada Y, Minamoto T, Oshima H, Oshima M. NF-κB-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells. Oncogene. 2019 Jan 30;38():4250–4263.

2018

  • Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2018 Nov 29;11(4): 267–276.
  • Sakai E, Nakayama M, Oshima H, Kouyama Y, Niida A, Fujii S, Ochiai A, Nakayama KI, Mimori K, Suzuki Y, Hong CP, Ock CY, Kim SJ, Oshima M. Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer. Cancer Res. 2018 Mar 1;78(5):1334-1346.

2017

  • Nakayama M, Sakai E, Echizen K, Yamada Y, Oshima H, Han TS, Ohki R, Fujii S, Ochiai A, Robine S, Voon DC, Tanaka T, Taketo MM, Oshima M. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation. Oncogene. 2017 Oct 19;36(42):5885-5896.

2016

  • Echizen K, Hirose O, Maeda Y, Oshima M. Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. Cancer Sci.2016 Apr;107(4):391-7.
  • Maeda Y, Echizen K, Oshima H, Yu L, Sakulsak N, Hirose O, Yamada Y, Taniguchi T, Jenkins BJ, Saya H, Oshima M.  Myeloid Differentiation Factor 88 Signaling in Bone Marrow-Derived Cells Promotes Gastric Tumorigenesis by Generation of Inflammatory Microenvironment. Cancer Prev Res(Phila). 2016 Mar;9(3):253-63.
  • Oshima H, Nakayama M, and Oshima M. The role of inflammation responses in mouse gastric tumorigenesis. Helicobacter pylori Research, Eds by Backert S, and Yamaoka Y. Springer, 325-338, 2016 (10.1007/978-4-431-55936-8)

2015

  • Oshima H, Nakayama M, Han TS, Naoi K, Ju X, Maeda Y, Robine S, Tsuchiya K, Sato T, Sato H, Taketo MM, Oshima M. Suppressing TGFβ signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer.  Cancer Res.2015 Feb 15;75(4):766-76.
  • Oshima H, and Oshima M. PGE2-associated inflammation and gastrointestinal tumorigenesis. Inflammtion and Immunity in Cancer, Eds by Seya T, Matsumoto M, Ueda K, and Sato N. Springer, 13-23, 2015 (DOI: 10.1007/978-4-431-55327-4)

2014

  • Ju X, Ishikawa T, Naka K, Ito K, Ito Y, and Oshima M. Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells. Cancer Sci,2014 Apr;105(4):418-24. doi: 10.1111/cas.12356. Epub 2014 Feb 18.

2013

  • Oshima H, Ishikawa T, Yoshida GJ, Naoi K, Maeda Y, Naka K, Ju X, Yamada Y, Minamoto T, Mukaida N, Saya H, and Oshima M. TNF-a/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells. Oncogene, 2013 Aug 26. 33: 3820-3829, 2014 (DOI: 10.1038/onc.2013.356).
  • Oshima H, and Oshima M. The role of PGE2-assocaited inflammatory responses in gastric cancer development. Semin Immunopathol, 35: 139-150, 2013.

2012

  • Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P, and Jenkins B. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell, 22: 466-478.
  • Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, Fushida S, Fujimura T, Minamoto T, Seno H, Yamada Y, Satou K, Ushijima T, Ishikawa TO, Oshima M. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene. 31: 3949-3960, 2012.
  • Oshima H, and Oshima M. The inflammatory network in the gastrointestinal microenvironment: Lessons from mouse models. J Gastroenterol. 47: 97-106, 2012.

2011

  • Oshima H, Hioki K, Popivanova BK, Oguma K, van Rooijen, N, Ishikawa T, and Oshima M. Prostaglandin E2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology, 140: 596-607, 2011.
  • Oshima H, Popivanova BK, Oguma K, Kong D, Ishikawa T, and Oshima M. Activation of epidermal growth factor receptor signaling by the prostaglandin E2 receptor EP4 pathway during gastric tumorigenesis. Cancer Sci, 102: 713-719, 2011.

2010

  • Oshima H, and Oshima M. Mouse models of gastric tumors: Wnt activation and PGE2 induction. Pathol Int, 60: 599-607, 2010.
  • Oguma K, Oshima H, and Oshima M. Inflammation, tumor necrosis factor and Wnt promotion in gastric cancer development. Future Oncology, 6: 515-526, 2010.

2009

  • Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, Piao YS, Yoshimoto T, Minamoto T, Kotani H, Taketo MM, and Oshima M. Induction and downregulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology, 137: 1346-1357, 2009.
  • Oshima H, Itadani H, Kotani H, Taketo MM, and Oshima M. Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res, 69: 2729-2733, 2009.
  • Oshima H, Oguma K, Du YC, and Oshima M. Prostaglandin E2, Wnt and BMP in gastric tumor mouse models. Cancer Sci, 100: 1779-1785, 2009. [Review]
  • Itadani H, Oshima H, Oshima, M, and Kotani H. Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics, 10: 615, 2009.

2008

  • Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, Hirao A, Saya H, Taketo MM, and Oshima M. Activated macrophages promote Wnt signaling through tumor necrosis factor-α in gastric tumor cell. EMBO J, 27: 1671-1681, 2008.
  • Guo X, Oshima H, Kitamura T, Taketo MM, and Oshima M. Stromal fibroblasts activated by tumor cells promotes angiogenesis in mouse gastric cancer. J Biol Chem, 283: 19864-19871, 2008.
  • Piao YS, Du YC, Oshima H, Jin JC, Nomura M, Yoshimoto T, and Oshima M. Platelet 12-lipoxygenase accelerates tumor promotion of mouse epidermal cells through enhancement of cloning efficiency. Carcinogenesis, 29: 440-447, 2008.
  • Oshima M, Oshima H, and Taketo MM. Prostaglandin and transforming growth factor-b signaling in gastric cancer. In Biology of Gastric Cancers,by Wang TC. et al. Springer, 513-540 , 2008.

2007

  • Oshima M, Suzuki H, Guo X, and Oshima H. Increased level of serum vascular endothelial growth factor by long-term exposure to hypergravity. Exp Anim, 56: 309-313, 2007.

2006

  • Oshima H, Matsunaga A, Fujumura T, Tsukamoto T, Taketo MM, and Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology, 131: 1086-1095, 2006.
  • Oshima H, Taketo MM, and Oshima M. Destruction of pancreatic β-cells by transgenic induction of prostaglandin E2 in the islets. J Biol Chem, 281: 29330-29336, 2006.

Articles before 2005

  • Oshima M, Oshima H, Matsunaga A, and Taketo MM. Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia (SPEM) caused by TNF-α-dependent inflammation in COX-2/mPGES-1 transgenic mice. Cancer Res, 65: 9147-9151, 2005.
  • Oshima H, Oshima M, Inaba K, and Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J, 23: 1669-1678, 2004.